Clinical Trial Update: Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant nab-paclitaxel and S-1 in resectable pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neoplasms

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Pancreatic Neoplasms | Phase 2 | Status: UNKNOWN